Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor

• Published in: Malaria journal 2019-04, Vol.18 (1), p.140-140, Article 140
• Main Authors: Chen, Nanhua, Dowd, Simone, Gatton, Michelle L, Auliff, Alyson, Edstein, Michael D, Cheng, Qin
• Format: Article
• Language: English
• Subjects: Alleles; Antimalarials - therapeutic use; Australia; Cohorts; CYP2D6 activity score; CYP2D6 allele; CYP2D6 phenotype; CYP2D6 protein; Cytochrome; Cytochrome P-450; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Cytochrome P450; Cytochromes; Deoxyribonucleic acid; DNA; DNA sequencing; Dosage and administration; Drug therapy; Gene frequency; Genotype & phenotype; Health aspects; Humans; Infections; Malaria; Malaria, Vivax - drug therapy; Metabolism; Metabolites; Military Personnel; Mutation; Nucleotide sequence; Papua New Guinea; Parasites; PCR; Peacekeeping forces; Personnel; Phenotypes; Plasmodium vivax; Population genetics; Primaquine; Primaquine - therapeutic use; Profiles; Recurrence; Relapses; Retrospective Studies; Serum; Timor-Leste; Treatment Outcome; Workers
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-019-2774-2

Primaquine, an 8-aminoquinoline with anti-hypnozoite activity against Plasmodium vivax, is metabolized by human cytochrome P450 2D6 (CYP2D6) to its active metabolite. Human CYP2D6 activities may influence the metabolism of primaquine and the risk of experiencing Plasmodium relapses following primaquine anti-relapse therapies (PART). In this study, the CYP2D6 profile and its relationship with outcomes of PART in Australian Defence Force (ADF) personnel is retrospectively investigated. Genomic DNA was isolated from stored and de-identified serum or blood samples from ADF personnel deployed on peacekeeping duties to Papua New Guinea (PNG) (1999) and East Timor (1999-2000) who received PART before returning to Australia and after experiencing relapses. CYP2D6 allelic type was determined by PCR and Sanger sequencing. CYP2D6 allele frequency, predicted phenotypes and activity scores were compared among personnel who did not experience P. vivax (ADF-NR, n = 48) and those who experience at least one (ADF-R, n = 109) relapse, as well as between those who experienced 1 (n = 79), 2 (n = 21) and 3-5 (n = 9) relapses within the ADF-R group. 16 CYP2D6 alleles were observed in 157 ADF personnel. Alleles *1, *4, *2 and *41 were major alleles (> 5%). The CYP2D6 allele frequency profile in the ADF-NR group matched that of a European population. There was an increased proportion of non-functional CYP2D6 alleles in the ADF-R group compared to the European population and ADF-NR group. However, frequencies of predicted CYP2D6 phenotype and activity score were not different between the ADF-R and ADF-NR groups, nor among sub-groups experiencing multiple relapses within the ADF-R group. CYP2D6 phenotype or activity score based on the allele classification was not a major contributor to P. vivax relapse in this ADF cohort. Other factors such as adherence and/or parasite tolerance to primaquine are likely contributing factors to P. vivax relapses in this cohort.